Aptose CEO disposes shares in Hammi acquisition

Q: How many Aptose Biosciences (APTOF) common shares did the CEO dispose of and at what price?

The CEO disposed of 613,252 Common Shares at $1.72 per share. This U.S. price reflects a Canadian consideration of C$2.41 per share, converted using an exchange rate of C$1.4 to US$1.00, as described in the filing footnotes.

Aptose Biosciences Inc.’s Chair, President & CEO William G. Rice disposed of his equity holdings in connection with the company’s acquisition by Hammi Pharmaceuticals.

Filing Impact

(Very High)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Aptose Biosciences Inc.’s Chair, President & CEO William G. Rice disposed of his equity holdings in connection with the company’s acquisition by Hammi Pharmaceuticals. He transferred 613,252 Common Shares at $1.72 per share, reflecting a Canadian price of C$2.41 converted at C$1.4 = US$1.00.

Rice also disposed of multiple stock option and warrant positions to the issuer on the same date, including large employee option grants and performance stock options with exercise prices ranging from $0.25 to $6.91 per share. Following these transactions, the filing shows zero shares and zero listed derivative awards remaining in his direct ownership, consistent with all outstanding shares of Aptose being acquired under a board, shareholder and court‑approved business arrangement with Hammi.

Insights

CEO’s equity is cashed out in a court‑approved Hammi acquisition, not through open‑market selling.

The filing shows William G. Rice, Aptose’s Chair, President & CEO, disposing of 613,252 Common Shares at $1.72 per share, tied to a Canadian price of C$2.41. Footnotes state this occurred under a board, shareholder and court‑approved business arrangement where a Hammi Pharmaceuticals subsidiary acquired all outstanding Aptose shares.

Rice’s numerous stock options, performance options and warrants, with exercise prices from $0.25 to $6.91, were also disposed of to the issuer, leaving no reported remaining derivative positions. Because these are mandatory deal‑closing mechanics rather than discretionary trades, they mainly confirm completion terms of the Hammi transaction rather than signaling a change in management’s view of the business.

Insider Trade Summary

Disposition: 6,026,252 shares

Disposition 13 txns

Insider Rice William G.

Role Chair, President & CEO

Type	Security	Shares	Price	Value
Disposition	Employee Stock Option ("Right to Buy")	70,000	$0.00	$0.00
Disposition	Warrants	50,000	$0.00	$0.00
Disposition	Employee Stock Option ("Right to Buy")	400,000	$0.00	$0.00
Disposition	Performance Stock Options	600,000	$0.00	$0.00
Disposition	Employee Option Grant	700,000	$0.00	$0.00
Disposition	Employee Stock Option ("Right to Buy")	343,000	$0.00	$0.00
Disposition	Employee Option Grant	2,000,000	$0.00	$0.00
Disposition	Stock Options (Right to Buy)	400,000	$0.00	$0.00
Disposition	Employee Stock Option (Right to Buy)	100,000	$0.00	$0.00
Disposition	Employee Stock Option (Right to Buy)	50,000	$0.00	$0.00
Disposition	Employee Stock Option (Right to Buy)	300,000	$0.00	$0.00
Disposition	Common Shares	400,000	$0.00	$0.00
Disposition	Common Shares	613,252	$1.72	$1.05M

Holdings After Transaction: Employee Stock Option ("Right to Buy") — 0 contracts (Direct); Warrants — 0 contracts (Direct); Performance Stock Options — 0 contracts (Direct); Employee Option Grant — 0 contracts (Direct); Stock Options (Right to Buy) — 0 contracts (Direct); Employee Stock Option (Right to Buy) — 0 contracts (Direct); Common Shares — 0 contracts (Direct); Common Shares — 0 shares (Direct)

Footnotes (3)

F1. Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Ltd., a South Korean corporation ("Hammi") whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a price of C$2.41 per share.
F2. Converted from Canadian price of C$2.41 per share using an exchange rate of C$1.4 = US$1.00.
F3. Options vest 50% on first anniversary of grant date; remaining options vest 1/3 annually beginning on the second anniversary of the grant date.

Key Figures

Common Shares disposed: 613,252 shares Per-share consideration (US): $1.72 per share Per-share consideration (CAD): C$2.41 per share +4 more

7 metrics

Common Shares disposed 613,252 shares Disposition to issuer at US$1.72 per share

Per-share consideration (US) $1.72 per share Converted from C$2.41 at C$1.4 = US$1.00

Per-share consideration (CAD) C$2.41 per share Price at which Hammi acquired all outstanding Aptose shares

Large option grant disposed 2,000,000 options Employee Option Grant, $6.91 exercise price, expiring 2030-01-30

Performance stock options disposed 600,000 options Performance Stock Options, $0.81 exercise price, expiring 2032-07-06

Low-strike warrants disposed 50,000 warrants Warrants with $0.25 exercise price, expiring 2029-11-25

Remaining reported holdings 0 shares/options Total shares following each transaction reported as 0.0000

Key Terms

Disposition to issuer, Employee Stock Option (Right to Buy), Performance Stock Options, business arrangement agreement, +1 more

5 terms

Disposition to issuer financial

"transaction_code_description": "Disposition to issuer""

Employee Stock Option (Right to Buy) financial

"security_title": "Employee Stock Option (Right to Buy)""

Performance Stock Options financial

"security_title": "Performance Stock Options""

business arrangement agreement financial

"business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Ltd."

court-approved regulatory

"board, shareholder and court-approved business arrangement agreement"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Aptose Biosciences (APTOF) CEO William G. Rice do in this Form 4?

William G. Rice disposed of his Aptose equity as part of a Hammi Pharmaceuticals acquisition. He transferred 613,252 Common Shares and multiple option and warrant positions back to the issuer in connection with a court‑approved business arrangement agreement.

How many Aptose Biosciences (APTOF) common shares did the CEO dispose of and at what price?

The CEO disposed of 613,252 Common Shares at $1.72 per share. This U.S. price reflects a Canadian consideration of C$2.41 per share, converted using an exchange rate of C$1.4 to US$1.00, as described in the filing footnotes.

What transaction involving Hammi Pharmaceuticals is disclosed for Aptose Biosciences (APTOF)?

A subsidiary of Hammi Pharmaceuticals acquired all outstanding Aptose shares at C$2.41 per share. The filing states this occurred under a board, shareholder and court‑approved business arrangement agreement, and Rice’s equity dispositions are recorded as part of that acquisition process.

Which Aptose Biosciences (APTOF) stock options and derivatives did the CEO dispose of?

The CEO disposed of several derivative awards, including large employee option grants, performance stock options and warrants. Exercise prices span from $0.25 to $6.91 per share, covering instruments such as Employee Stock Options, Employee Option Grants, Performance Stock Options and Warrants tied to Common Shares.

Does the Aptose Biosciences (APTOF) CEO still hold shares or options after these transactions?

According to the filing, total shares following each reported transaction are zero, and no remaining derivative positions are listed. This indicates Rice no longer holds the reported Common Shares or the specified stock option and warrant awards after completion of the Hammi business arrangement.

Were the Aptose Biosciences (APTOF) CEO’s transactions open‑market trades?

No, the transactions are coded as “Disposition to issuer” and footnotes tie them to a business arrangement agreement with Hammi Pharmaceuticals. That means they are deal‑driven dispositions associated with a court‑approved acquisition, not discretionary open‑market buying or selling by the CEO.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 07/01/2026 - 05:01 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rice William G.

(Last)

(First)

(Middle)

C/O APTOSE BIOSCIENCES INC.

251 CONSUMERS ROAD, SUITE 1105

(Street)

TORONTO

M2J 4R3

(City)

(State)

(Zip)

ONTARIO, CANADA

(Country)

2. Issuer Name and Ticker or Trading Symbol
Aptose Biosciences Inc. [ APTO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chair, President & CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Shares	06/30/2026		D⁽¹⁾		613,252	D	$1.72⁽²⁾	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Employee Stock Option ("Right to Buy")	$2	06/30/2026		D⁽¹⁾			70,000	⁽³⁾	02/05/2034	Common Shares	70,000	$0	0	D
Warrants	$0.25	06/30/2026		D⁽¹⁾			50,000	11/25/2024	11/25/2029	Common Shares	500,000	$0	0	D
Employee Stock Option ("Right to Buy")	$0.66	06/30/2026		D⁽¹⁾			400,000	⁽³⁾	01/29/2033	Common Shares	400,000	$0	0	D
Performance Stock Options	$0.81	06/30/2026		D⁽¹⁾			600,000	⁽³⁾	07/06/2032	Common Shares	600,000	$0	0	D
Employee Option Grant	$1.34	06/30/2026		D⁽¹⁾			700,000	⁽³⁾	01/17/2032	Common Shares	700,000	$0	0	D
Employee Stock Option ("Right to Buy")	$4.37	06/30/2026		D⁽¹⁾			343,000	⁽³⁾	01/04/2031	Common Shares	343,000	$0	0	D
Employee Option Grant	$6.91	06/30/2026		D⁽¹⁾			2,000,000	⁽³⁾	01/30/2030	Common Shares	2,000,000	$0	0	D
Stock Options (Right to Buy)	$1.91	06/30/2026		D⁽¹⁾			400,000	⁽³⁾	01/02/2029	Common Shares	400,000	$0	0	D
Employee Stock Option (Right to Buy)	$1.14	06/30/2026		D⁽¹⁾			100,000	⁽³⁾	03/28/2027	Common Shares	100,000	$0	0	D
Employee Stock Option (Right to Buy)	$1.03	06/30/2026		D⁽¹⁾			50,000	⁽³⁾	06/06/2027	Common Shares	50,000	$0	0	D
Employee Stock Option (Right to Buy)	$2.8	06/30/2026		D⁽¹⁾			300,000	⁽³⁾	01/19/2028	Common Shares	300,000	$0	0	D
Common Shares	$3.07	06/30/2026		D⁽¹⁾			400,000	⁽³⁾	01/22/2028	Common Shares	400,000	$0	0	D

Explanation of Responses:

1. Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Ltd., a South Korean corporation ("Hammi") whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a price of C$2.41 per share.

2. Converted from Canadian price of C$2.41 per share using an exchange rate of C$1.4 = US$1.00.

3. Options vest 50% on first anniversary of grant date; remaining options vest 1/3 annually beginning on the second anniversary of the grant date.

Remarks:

TOTAL OPTIONS AND OPTION EXERCISE PRICE SUBJECT TO ADJUSTMENT AS A RESULT OF THE ISSUER'S 1:30 REVERSE STOCK SPLIT ON 2/26/25, AND THE ISSUER'S 1:15 REVERSE STOCK SPLIT ON 6/6/2023

	/s/ William G. Rice	06/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

Aptose CEO disposes shares in Hammi acquisition

Rhea-AI Filing Summary